Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Fujimoto D, et al. Among authors: taniguchi y. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi: 10.1001/jamanetworkopen.2023.0698. JAMA Netw Open. 2023. PMID: 36826813 Free PMC article.
Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC.
Kuge T, Shiroyama T, Tamiya A, Tamiya M, Kanazu M, Kinehara Y, Tanaka T, Morimura O, Taniguchi Y, Niki T, Tetsumoto S, Hayashi K, Nishino K, Nagatomo I, Kumanogoh A. Kuge T, et al. Among authors: taniguchi y. JTO Clin Res Rep. 2023 Mar 23;4(5):100505. doi: 10.1016/j.jtocrr.2023.100505. eCollection 2023 May. JTO Clin Res Rep. 2023. PMID: 37284296 Free PMC article.
Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC.
Kinehara Y, Shiroyama T, Tamiya A, Tamiya M, Minami S, Kanazu M, Morimura O, Niki T, Tetsumoto S, Taniguchi Y, Kuge T, Nishino K, Nagatomo I, Kumanogoh A, Tachibana I. Kinehara Y, et al. Among authors: taniguchi y. JTO Clin Res Rep. 2023 Oct 12;4(11):100586. doi: 10.1016/j.jtocrr.2023.100586. eCollection 2023 Nov. JTO Clin Res Rep. 2023. PMID: 38029024 Free PMC article.
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.
Shibaki R, Fujimoto D, Nozawa T, Sano A, Kitamura Y, Fukuoka J, Sato Y, Kijima T, Matsumoto H, Yokoyama T, Miura S, Hata A, Tamiya M, Taniguchi Y, Sugisaka J, Furuya N, Tanaka H, Yamamoto N, Koh Y, Akamatsu H. Shibaki R, et al. Among authors: taniguchi y. J Immunother Cancer. 2024 Feb 15;12(2):e007987. doi: 10.1136/jitc-2023-007987. J Immunother Cancer. 2024. PMID: 38360040 Free PMC article.
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K. Kawachi H, et al. Among authors: taniguchi y. Clin Lung Cancer. 2024 Nov;25(7):643-652.e4. doi: 10.1016/j.cllc.2024.07.014. Epub 2024 Jul 25. Clin Lung Cancer. 2024. PMID: 39138106
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Taniguchi Y, et al. BMC Pulm Med. 2024 Aug 24;24(1):407. doi: 10.1186/s12890-024-03212-5. BMC Pulm Med. 2024. PMID: 39182046 Free PMC article.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Shibaki R, Fujimoto D, Miyauchi E, Tsukita Y, Nakachi I, Arai D, Sakata Y, Shingu N, Shimokawa T, Kijima T, Tamiya M, Kawana S, Hara S, Saito G, Sato Y, Yokoyama T, Sakata S, Taniguchi Y, Hata A, Matsumoto H, Yamaguchi T, Yamamoto N. Shibaki R, et al. Among authors: taniguchi y. Lung Cancer. 2024 Oct;196:107958. doi: 10.1016/j.lungcan.2024.107958. Epub 2024 Sep 19. Lung Cancer. 2024. PMID: 39312871 Clinical Trial.
Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Taniguchi Y, Nosaki K, Fukumitsu K, Akechi T. Hasegawa T, et al. Among authors: taniguchi y. Oncologist. 2024 Feb 2;29(2):e282-e289. doi: 10.1093/oncolo/oyad245. Oncologist. 2024. PMID: 37669003 Free PMC article.
2,514 results